16:17 , Sep 8, 2017 |  BC Week In Review  |  Financial News

Nightstar, Deciphera, NuCana propose NASDAQ IPOs

Ophthalmic gene therapy company Nightstar Therapeutics Ltd. (London, U.K.) (formerly NightstaRx Ltd.) filed to raise up to $86.3 million on Aug. 31 in an IPO on NASDAQ underwritten by Jefferies, Leerink, BMO Capital Markets, Wedbush...
21:35 , Sep 1, 2017 |  BC Extra  |  Financial News

Nightstar, Deciphera, NuCana propose NASDAQ IPOs

Ophthalmic gene therapy company Nightstar Therapeutics Ltd. (London, U.K.) (formerly NightstaRx Ltd.) filed to raise up to $86.3 million on Thursday in an IPO on NASDAQ underwritten by Jefferies, Leerink, BMO Capital Markets, Wedbush and...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

Acelarin: Phase Ib data

Data from 20 evaluable patients with recurrent platinum-resistant ovarian cancer in the open-label, dose-escalation, U.K. Phase Ib ProGem2 trial showed that Acelarin given on days 1 and 8 every 21 days plus carboplatin led to...
00:47 , Jul 2, 2015 |  BC Extra  |  Company News

Management tracks

Cancer play NuCana BioMed Ltd. (Edinburgh, U.K.) named Chris McGuigan CSO. McGuigan is professor of medicinal chemistry at the Cardiff School of Pharmacy and Pharmaceutical Sciences and chair of Life Sciences Hub Wales Ltd. (Cardiff,...
01:38 , Jun 23, 2015 |  BC Extra  |  Company News

Management tracks

Rare disease play Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) named Jayson Dallas chief commercial officer, effective Aug. 3. Dallas was general manager in the U.K. at Roche (SIX:ROG; OTCQX:RHHBY). Hepatic company Intercept Phamaceuticals Inc. (NASDAQ:ICPT) named Juan...
07:00 , Jun 8, 2015 |  BC Week In Review  |  Clinical News

Acelarin: Phase I/II final data

Final data from an open-label, U.K. Phase I/II trial in 49 evaluable patients with advanced solid tumors showed that IV Acelarin led to a disease control rate (DCR) of 78%, including 5 partial responses and...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Financial News

Sofinnova Ventures financial update

Sofinnova raised $440 million for its eighth fund and first life sciences-only fund in 2011. The firm’s portfolio includes biosimilar play Coherus BioSciences Inc. (Redwood City, Calif.), gene therapy company Spark Therapeutics LLC (Philadelphia, Pa.)...
07:00 , Jul 28, 2014 |  BioCentury  |  Finance

Staying the course with half a billion

Sofinnova Ventures is sticking with what works for its second life sciences-only fund, which the firm closed last week at $500 million. The fund, the firm's ninth overall, was oversubscribed and was originally targeting $425...
00:58 , Jul 24, 2014 |  BC Extra  |  Financial News

Sofinnova raises $500 million for ninth fund

Sofinnova Ventures raised $500 million for Sofinnova Venture Partners IX, its ninth fund and second life sciences-only fund. The firm was targeting $425 million for the fund, which was oversubscribed. Sofinnova plans to invest the...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Financial News

Sofinnova Ventures financial update

Sofinnova Ventures , Menlo Park, Calif.   Business: Finance   Date announced: 2014-07-10   Note: Sofinnova Ventures is looking to raise $500 million for a ninth fund, according to an SEC filing. The firm raised...